Neuren Pharmaceuticals

NEU · ASX · AUD

$20.28+0.70%+$0.14

Close · October 2, 2026

Latest news

Neuren Pharmaceuticals Limited (ASX:NEU): First Dividend Arrives as Phase 3 Investment Accelerates (opens in a new tab)
Kalkine · Oct 1, 2026
What Will Its First European Launch Mean for Neuren (ASX:NEU)? (opens in a new tab)
Kalkine Media · Sep 30, 2026
Neuren Pharmaceuticals (ASX:NEU): How Could the New Trofinetide Patent Extend Protection? (opens in a new tab)
Kalkine · Sep 29, 2026
Neuren Pharmaceuticals (ASX:NEU): US Patent Allowance Supports Potential Trofinetide Protection Extension (opens in a new tab)
Kalkine · Sep 29, 2026
What lies ahead for Neuren (ASX:NEU) as FDA talks draw near? (opens in a new tab)
Kalkine Media · Sep 28, 2026
Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best? (opens in a new tab)
The Motley Fool Australia · Sep 21, 2026
What Could Neuren Pharmaceuticals (ASX:NEU) Mean for Midcaps? (opens in a new tab)
Kalkine Media · Sep 17, 2026
Sigma Healthcare, Neuren and Mesoblast: Financial Performance Across ASX Healthcare (opens in a new tab)
Kalkine · Sep 14, 2026
ASX Healthcare Stocks to Watch in September 2026: Sigma Healthcare (ASX:SIG), Neuren Pharmaceuticals (ASX:NEU) and Mesoblast (ASX:MSB) (opens in a new tab)
Kalkine · Sep 14, 2026
Neuren Pharmaceuticals (ASX:NEU): DAYBUE Royalties and NNZ-2591 Pipeline Define the Growth Story (opens in a new tab)
Kalkine · Sep 7, 2026
Neuren Pharmaceuticals (ASX:NEU) Up 1.51% — Royalties and NNZ-2591 Pipeline in the Spotlight (opens in a new tab)
Kalkine · Sep 4, 2026